JP5570429B2 - デオキシシチジン誘導体を含有する抗腫瘍剤を投与する方法 - Google Patents
デオキシシチジン誘導体を含有する抗腫瘍剤を投与する方法 Download PDFInfo
- Publication number
- JP5570429B2 JP5570429B2 JP2010535152A JP2010535152A JP5570429B2 JP 5570429 B2 JP5570429 B2 JP 5570429B2 JP 2010535152 A JP2010535152 A JP 2010535152A JP 2010535152 A JP2010535152 A JP 2010535152A JP 5570429 B2 JP5570429 B2 JP 5570429B2
- Authority
- JP
- Japan
- Prior art keywords
- patient
- administered
- antitumor agent
- cyano
- pyrimidinone
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
癌患者へ3週間に1回、CNDAC(遊離塩基)換算量で2.0〜4.0mg/m2/日の量を336時間かけて持続静脈内注入によって抗腫瘍剤を投与することを1コースとして、繰り返し行った場合の有害事象の発症頻度と治療効果を検討した。
2週間のうちに1回1日当たり、体表面積の1m2に対してCADAC(遊離塩基)換算量の3.0〜4.0mgの量を、168時間かけて持続静脈内注入によって投与することを1コースとして、繰り返し行った場合の有害事象の発症頻度と治療効果を検討した。なお、本試験の対象患者、評価方法及び評価基準は実施例1の試験と同様である。
担癌ラットモデルにおけるCNDACの急速静脈内注入と持続静脈内注入での抗腫瘍効果を検討した。ヒト肺癌株LX−1担癌ラットに投与されたCNDAC急速静脈内注入と持続静脈内注入での抗腫瘍効果の検討を行った結果を図1に示す。
ヒト結腸癌株KM20C担癌ラットに投与したCNDACとゲムシタビンの持続静脈内注入における抗腫瘍効果を比較検討した。結果を図2に示す。
ヒト膵癌株PAN−4担癌ラットに投与したCNDACの持続静脈内注入における抗腫瘍効果と副作用(体重抑制)の関係を検討した。結果を図3及び4に示す。
Claims (6)
- 4−アミノ−1−(2−シアノ−2−デオキシ−β−D−アラビノフラノシル)−2(1H)−ピリミジノン又はその塩を含有する抗腫瘍剤を、患者に対して、1日当たり該患者の体表面積1m2に対して4−アミノ−1−(2−シアノ−2−デオキシ−β−D−アラビノフラノシル)−2(1H)−ピリミジノン換算量で2.0mgの量を336時間持続静脈内投与するための組成物。
- 前記患者に対して、前記抗腫瘍剤を1治療コースとして3週間に1回投与し、該治療コースを少なくとも2回行う請求項1記載の抗腫瘍剤を持続静脈内投与するための組成物。
- 4−アミノ−1−(2−シアノ−2−デオキシ−β−D−アラビノフラノシル)−2(1H)−ピリミジノン又はその塩を含有する抗腫瘍剤を、患者に対して、1日当たり該患者の体表面積1m2に対して4−アミノ−1−(2−シアノ−2−デオキシ−β−D−アラビノフラノシル)−2(1H)−ピリミジノン換算量で3.0mgの量を168時間持続静脈内投与するための組成物。
- 前記患者に対して、前記抗腫瘍剤を1治療コースとして2週間に1回投与し、該治療コースを少なくとも2回行う請求項3記載の抗腫瘍剤を持続静脈内投与するための組成物。
- 生理学的に許容される抗腫瘍剤静脈内搬送用液状媒体で希釈した、4−アミノ−1−(2−シアノ−2−デオキシ−β−D−アラビノフラノシル)−2(1H)−ピリミジノン又はその塩を含有する容器を含む抗腫瘍剤を、患者に対して、1日当たり患者の体表面積1m2に対して4−アミノ−1−(2−シアノ−2−デオキシ−β−D−アラビノフラノシル)−2(1H)−ピリミジノン換算量で2.0mgの量を336時間持続静脈内投与するための組成物。
- 生理学的に許容される抗腫瘍剤静脈内搬送用液状媒体で希釈した、4−アミノ−1−(2−シアノ−2−デオキシ−β−D−アラビノフラノシル)−2(1H)−ピリミジノン又はその塩を含有する容器を含む抗腫瘍剤を、患者に対して、1日当たり患者の体表面積1m2に対して4−アミノ−1−(2−シアノ−2−デオキシ−β−D−アラビノフラノシル)−2(1H)−ピリミジノン換算量で3.0mgの量を168時間持続静脈内投与するための組成物。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12/111,369 US7863255B2 (en) | 2008-04-29 | 2008-04-29 | Methods of administering antitumor agent comprising deoxycytidine derivative |
US12/111,369 | 2008-04-29 | ||
PCT/JP2009/058725 WO2009133963A1 (en) | 2008-04-29 | 2009-04-28 | Methods of administering antitumor agent comprising deoxycytidine derivative |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2011518761A JP2011518761A (ja) | 2011-06-30 |
JP2011518761A5 JP2011518761A5 (ja) | 2012-01-26 |
JP5570429B2 true JP5570429B2 (ja) | 2014-08-13 |
Family
ID=41050984
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2010535152A Active JP5570429B2 (ja) | 2008-04-29 | 2009-04-28 | デオキシシチジン誘導体を含有する抗腫瘍剤を投与する方法 |
Country Status (8)
Country | Link |
---|---|
US (1) | US7863255B2 (ja) |
EP (1) | EP2268287B1 (ja) |
JP (1) | JP5570429B2 (ja) |
AU (1) | AU2009240908B2 (ja) |
DK (1) | DK2268287T3 (ja) |
ES (1) | ES2467968T3 (ja) |
PL (1) | PL2268287T3 (ja) |
WO (1) | WO2009133963A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2022014025A1 (ja) | 2020-07-17 | 2022-01-20 | Delta-Fly Pharma株式会社 | 血液がんの新規治療法及び新規治療剤 |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0625283D0 (en) | 2006-12-19 | 2007-01-24 | Cyclacel Ltd | Combination |
JP2014001204A (ja) * | 2012-05-23 | 2014-01-09 | Kumamoto Univ | 腫瘍細胞選択的抗がん剤 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2559917B2 (ja) | 1990-06-15 | 1996-12-04 | 三共株式会社 | ピリミジンヌクレオシド誘導体 |
GB0328180D0 (en) * | 2003-12-04 | 2004-01-07 | Cyclacel Ltd | Combination |
GB0609530D0 (en) * | 2006-05-12 | 2006-06-21 | Cyclacel Ltd | Combination |
-
2008
- 2008-04-29 US US12/111,369 patent/US7863255B2/en active Active
-
2009
- 2009-04-28 ES ES09738900.1T patent/ES2467968T3/es active Active
- 2009-04-28 WO PCT/JP2009/058725 patent/WO2009133963A1/en active Application Filing
- 2009-04-28 AU AU2009240908A patent/AU2009240908B2/en active Active
- 2009-04-28 JP JP2010535152A patent/JP5570429B2/ja active Active
- 2009-04-28 DK DK09738900.1T patent/DK2268287T3/da active
- 2009-04-28 EP EP09738900.1A patent/EP2268287B1/en active Active
- 2009-04-28 PL PL09738900T patent/PL2268287T3/pl unknown
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2022014025A1 (ja) | 2020-07-17 | 2022-01-20 | Delta-Fly Pharma株式会社 | 血液がんの新規治療法及び新規治療剤 |
US11957701B2 (en) | 2020-07-17 | 2024-04-16 | Delta-Fly Pharma, Inc. | Therapy and new therapeutic agent for blood cancer |
Also Published As
Publication number | Publication date |
---|---|
DK2268287T3 (da) | 2014-06-02 |
AU2009240908A1 (en) | 2009-11-05 |
PL2268287T3 (pl) | 2014-10-31 |
WO2009133963A1 (en) | 2009-11-05 |
US20090270340A1 (en) | 2009-10-29 |
EP2268287A1 (en) | 2011-01-05 |
JP2011518761A (ja) | 2011-06-30 |
US7863255B2 (en) | 2011-01-04 |
EP2268287B1 (en) | 2014-05-21 |
AU2009240908B2 (en) | 2013-10-03 |
ES2467968T3 (es) | 2014-06-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2705016T3 (es) | Derivado de rapamicina para el tratamiento de cáncer de pulmón | |
CN105338977A (zh) | 艾日布林和乐伐替尼作为治疗癌症的联合疗法的用途 | |
EP3449919B1 (en) | Method for treating pleuroperitoneal membrane cancers by locally injecting disulfiram preparation | |
KR102308387B1 (ko) | 고시폴, 펜포르민 및 항암제를 포함하는 암 예방 또는 치료용 약학적 조성물 | |
JP5570429B2 (ja) | デオキシシチジン誘導体を含有する抗腫瘍剤を投与する方法 | |
US11141421B2 (en) | Antitumor agent for biliary tract cancer and method for treating biliary tract cancer | |
Moehler et al. | New chemotherapeutic strategies in colorectal cancer | |
KR101065932B1 (ko) | 방사선 치료 증강제 | |
WO1992011247A1 (en) | Anticancer composition and compound | |
JP5066737B2 (ja) | シチジン誘導体を含有する持続静脈内投与用抗腫瘍剤 | |
JP2010526073A (ja) | 癌または前癌性症状およびその他の症状の治療のためのジヒドロピリジン誘導体 | |
JP2021533112A (ja) | 癌を治療するための併用療法 | |
TW202000207A (zh) | 膀胱癌用抗腫瘤劑及膀胱癌的處置方法 | |
JP5581200B2 (ja) | シチジン誘導体及びカルボプラチンを含有する抗腫瘍剤 | |
WO2022014025A1 (ja) | 血液がんの新規治療法及び新規治療剤 | |
EP2431032A1 (en) | Anti-tumor agent comprising tegafur-gimeracil-oteracil potassium combination drug and oxaliplatin | |
JPS6337767B2 (ja) | ||
TW202203942A (zh) | 血液癌之新穎治療法及新穎治療劑 | |
JP2006518355A (ja) | インドロピロロカルバゾール誘導体及び他の抗腫瘍薬を含む併用療法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20110328 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20110328 |
|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20111004 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20111004 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20111201 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20111201 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20130604 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130724 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20131126 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140107 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20140617 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20140624 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5570429 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100917 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |